Five Prime Therapeutics Inc. (FPRX)

9.05
NASDAQ : Health Technology
Prev Close 8.81
Day Low/High 8.86 / 9.12
52 Wk Low/High 7.84 / 18.78
Avg Volume 302.40K
Exchange NASDAQ
Shares Outstanding 36.06M
Market Cap 317.72M
EPS -4.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Five Prime Therapeutics Announces FPA150 Poster Presentation At The 2019 ASCO Annual Meeting

Five Prime Therapeutics Announces FPA150 Poster Presentation At The 2019 ASCO Annual Meeting

Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced an upcoming poster presentation at the 2019 ASCO Annual Meeting...

Relative Strength Alert For Five Prime Therapeutics

Relative Strength Alert For Five Prime Therapeutics

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Five Prime Therapeutics Reports First Quarter 2019 Results

Five Prime Therapeutics Reports First Quarter 2019 Results

Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced its results for the first quarter and provided an update on the...

Five Prime Therapeutics To Announce First Quarter 2019 Financial Results And Host Conference Call On May 8

Five Prime Therapeutics To Announce First Quarter 2019 Financial Results And Host Conference Call On May 8

Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, will report its first quarter 2019 financial results on Wednesday, May 8, 2019,...

First Week Of FPRX May 17th Options Trading

First Week Of FPRX May 17th Options Trading

Investors in Five Prime Therapeutics, Inc saw new options begin trading this week, for the May 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the FPRX options chain for the new May 17th contracts and identified one put and one call contract of particular interest.

Bullish Two Hundred Day Moving Average Cross - FPRX

Bullish Two Hundred Day Moving Average Cross - FPRX

In trading on Wednesday, shares of Five Prime Therapeutics, Inc crossed above their 200 day moving average of $13.19, changing hands as high as $13.25 per share. Five Prime Therapeutics, Inc shares are currently trading up about 2.3% on the day.

Five Prime Therapeutics To Present At Cowen And Company 39th Annual Health Care Conference

Five Prime Therapeutics To Present At Cowen And Company 39th Annual Health Care Conference

Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics today announced that Aron Knickerbocker, Chief Executive Officer of Five Prime...

Five Prime Therapeutics Reports Fourth Quarter And Full Year 2018 Financial Results

Five Prime Therapeutics Reports Fourth Quarter And Full Year 2018 Financial Results

Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced its financial results for the fourth quarter and year ended...

Five Prime Therapeutics Doses First Patient In Phase 1b Trial Of FPA150

Five Prime Therapeutics Doses First Patient In Phase 1b Trial Of FPA150

Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced that it initiated patient dosing in the Phase 1b dose expansion...

Five Prime Therapeutics To Announce Fourth Quarter And Full Year 2018 Financial Results And Host Conference Call On February 26

Five Prime Therapeutics To Announce Fourth Quarter And Full Year 2018 Financial Results And Host Conference Call On February 26

Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, will report its fourth quarter and full year 2018 financial results on Tuesday,...

Five Prime Therapeutics To Present At The Guggenheim Healthcare Talks Idea Forum

Five Prime Therapeutics To Present At The Guggenheim Healthcare Talks Idea Forum

Five Prime Therapeutics, Inc. (NASDAQ:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics today announced that Aron Knickerbocker, Chief Executive Officer, will present at the...

Five Prime Therapeutics Presents Data From Safety Lead-in To Phase 3 FIGHT Trial Of Bemarituzumab At 2019 American Society Of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium

Five Prime Therapeutics Presents Data From Safety Lead-in To Phase 3 FIGHT Trial Of Bemarituzumab At 2019 American Society Of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium

Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, announced today that a poster entitled "Phase 1 Results from the Phase 1/3 FIGHT...

Five Prime Announces Restructuring To Focus On Clinical Development And Later-Stage Research Priorities

Five Prime Announces Restructuring To Focus On Clinical Development And Later-Stage Research Priorities

Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, announced today a corporate restructuring to focus resources on its development...

Five Prime Therapeutics Announces Two Poster Presentations At The 2019 Gastrointestinal Cancers Symposium

Five Prime Therapeutics Announces Two Poster Presentations At The 2019 Gastrointestinal Cancers Symposium

Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced two upcoming presentations at the 2019 Gastrointestinal Cancer...

Five Prime Therapeutics To Present At The 37th Annual J.P. Morgan Healthcare Conference

Five Prime Therapeutics To Present At The 37th Annual J.P. Morgan Healthcare Conference

Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today announced that Aron Knickerbocker, Chief Executive Officer, will present at the 37 th...

Five Prime Therapeutics Announces Changes To Its Board Of Directors

Five Prime Therapeutics Announces Changes To Its Board Of Directors

Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, announced today changes to its Board of Directors.

Five Prime Therapeutics To Present At 30th Annual Piper Jaffray Healthcare Conference

Five Prime Therapeutics To Present At 30th Annual Piper Jaffray Healthcare Conference

Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today announced that Aron Knickerbocker, Chief Executive Officer, will present at the 30 th...

Five Prime Therapeutics Initiates Patient Dosing In A Phase 1 Clinical Trial Of FPT155, A First-in-Class CD80 Fusion Protein

Five Prime Therapeutics Initiates Patient Dosing In A Phase 1 Clinical Trial Of FPT155, A First-in-Class CD80 Fusion Protein

Five Prime Therapeutics, Inc. (Nasdaq: FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today announced it initiated patient dosing in a Phase 1 clinical trial of FPT155, a first-in-class CD80...

Five Prime Therapeutics Announces Third Quarter 2018 Financial Results

Five Prime Therapeutics Announces Third Quarter 2018 Financial Results

Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today provided a corporate update and reported financial results for the fiscal...

Five Prime Therapeutics Announces David V. Smith Will Join As Chief Financial Officer

Five Prime Therapeutics Announces David V. Smith Will Join As Chief Financial Officer

Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced that industry veteran David V.

Five Prime Therapeutics To Announce Third Quarter 2018 Financial Results And Host Conference Call On November 6

Five Prime Therapeutics To Announce Third Quarter 2018 Financial Results And Host Conference Call On November 6

Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, will report its third quarter 2018 financial results on Tuesday, Nov.

Five Prime Therapeutics Initiates Patient Dosing In The Dose Exploration Cohort Of Its Phase 1 Trial Of Novel First-in-Class B7-H4 Antibody FPA150

Five Prime Therapeutics Initiates Patient Dosing In The Dose Exploration Cohort Of Its Phase 1 Trial Of Novel First-in-Class B7-H4 Antibody FPA150

Five Prime Therapeutics, Inc. (Nasdaq: FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today announced that it initiated patient dosing in the dose exploration cohort of its ongoing Phase 1...

Five Prime Therapeutics And Zai Lab Dosed First Patient In Phase 3, Global Registrational Trial Of Bemarituzumab In Front-Line Advanced Gastric And Gastroesophageal Junction Cancers

Five Prime Therapeutics And Zai Lab Dosed First Patient In Phase 3, Global Registrational Trial Of Bemarituzumab In Front-Line Advanced Gastric And Gastroesophageal Junction Cancers

Five Prime Therapeutics, Inc. (Nasdaq: FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, and Zai Lab Limited (Nasdaq: ZLAB), a Shanghai-based innovative biopharmaceutical company, today announced...

Five Prime Therapeutics To Present At Leerink Partners Roundtable Series: Rare Disease & Oncology

Five Prime Therapeutics To Present At Leerink Partners Roundtable Series: Rare Disease & Oncology

Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today announced that Aron Knickerbocker, Chief Executive Officer, will present at the Leerink Partners...

Five Prime Therapeutics Is Now Oversold (FPRX)

Five Prime Therapeutics Is Now Oversold (FPRX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Five Prime Therapeutics Completes Phase 1 Safety Lead-In And Initiates Phase 3, Global Registrational Trial Of Bemarituzumab In Front-Line Advanced Gastric And Gastroesophageal Junction Cancers

Five Prime Therapeutics Completes Phase 1 Safety Lead-In And Initiates Phase 3, Global Registrational Trial Of Bemarituzumab In Front-Line Advanced Gastric And Gastroesophageal Junction Cancers

Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today announced that the company completed the Phase 1 safety lead-in portion and has initiated the Phase 3...

Five Prime Therapeutics To Present At 2018 Wells Fargo Healthcare Conference

Five Prime Therapeutics To Present At 2018 Wells Fargo Healthcare Conference

Five Prime Therapeutics, Inc. (Nasdaq: FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today announced that Aron Knickerbocker, Chief Executive Officer, will present at the 2018 Wells Fargo...

Five Prime Therapeutics Announces Second Quarter 2018 Financial Results

Five Prime Therapeutics Announces Second Quarter 2018 Financial Results

Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today provided a corporate update and reported financial results for the fiscal...

TheStreet Quant Rating: D (Sell)